<DOC>
	<DOCNO>NCT00547157</DOCNO>
	<brief_summary>The purpose study estimate , pre-specified precision , difference local-regional control ( LRC ) rate 2 year subject receive chemoradiotherapy ( CRT ) panitumumab plus radiotherapy ( PRT ) first line treatment locally advance squamous cell carcinoma head neck ( SCCHN ) . A formal hypothesis test trial ; however , treatment arm difference LRC rate 2 year estimate .</brief_summary>
	<brief_title>Radiotherapy Plus Panitumumab Compared Chemoradiotherapy With Unresected , Locally Advanced Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>Primary Objective : To estimate , pre-specified precision , difference local-regional control ( LRC ) rate 2 year subject receive chemoradiotherapy ( CRT ) panitumumab plus radiotherapy ( PRT ) first line treatment locally advance squamous cell carcinoma head neck ( SCCHN ) . Secondary Objectives : To estimate difference 2 treatment regimen ( CRT v PRT ) measure clinical benefit , include LRC , overall response rate ( ORR ) , progression-free survival ( PFS ) , overall survival ( OS ) ; safety . Tertiary Objectives : To estimate difference health-related quality life ( HRQoL ) performance status subject receive PRT CRT . Exploratory Objectives : To investigate potential biomarker development base assessment blood tumor propose mechanism action study drug . In addition , investigate effect genetic variation cancer gene drug target gene SCCHN subject response study drug ( separate inform consent require ) . Hypothesis : A formal hypothesis test trial ; however , treatment arm difference LRC rate 2 year estimate . Study Design : This phase 2 , open-label , randomize , multicenter study . Eligible subject randomize 2:3 ratio either follow regimen : Arm 1 CRT : - Accelerated fractionation RT : 70 72 Gy - deliver 6 6.5 week - Cisplatin : 100 mg/m2 ( give day 1 22 RT ) Arm 2 PRT : - Accelerated fractionation RT : 70 72 Gy - deliver 6 6.5 week - Panitumumab : 9.0 mg/kg Q3W ( give day 1 , 22 , 43 RT )</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm SCC oral cavity , oropharynx , hypopharynx larynx Stage III Stage IVab ( M0 ) disease accord American Joint Committee Cancer stag manual 6th edition ( locally advance ) ECOG performance status 0 1 Bidimensionally measurable disease &gt; /= 10 mm least 1 dimension NO Primary tumor nasopharynx , sinus , salivary gland , skin NO Subjects require prophylactic tracheostomy NO Prior ( concomitant ) malignancy ( except nonmelanomatous skin cancer situ cervical cancer ) , study disease ( SCCHN ) , unless treat curative intent evidence disease &gt; /= 3 year NO Prior treatment locally advance SSCHN NO Prior surgery SCCHN ( except nodal sample biopsy study disease ) NO Major surgery &lt; /= 28 day randomization minor surgery &lt; /= 14 day randomization exception feed tube placement , dental extraction , central venous catheter placement , biopsy nodal sample</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>head neck</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemoradiotherapy</keyword>
	<keyword>panitumumab</keyword>
	<keyword>locally advanced head &amp; neck cancer</keyword>
	<keyword>EGFr</keyword>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>SCCHN</keyword>
	<keyword>locally advanced SCCHN</keyword>
	<keyword>HNC</keyword>
	<keyword>epidermal growth factor</keyword>
</DOC>